[8-K] UroGen Pharma Ltd. Reports Material Event

UroGen Pharma (URGN) reported that it announced financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

UroGen Pharma (URGN) reported that it announced financial results for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1.

The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. UroGen’s ordinary shares trade on Nasdaq under the symbol URGN.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

What did UroGen Pharma (URGN) announce?

The company announced financial results for the quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1.

Where can I find the detailed results for URGN’s quarter?

Details are in the press release attached as Exhibit 99.1.

How is the information treated under the Exchange Act?

The information was furnished under Item 2.02 and is not deemed “filed” under Section 18.

What period do the results cover for URGN?

They cover the quarter ended September 30, 2025.

What is UroGen Pharma’s trading symbol and exchange?

UroGen’s ordinary shares trade on Nasdaq under the symbol URGN.

When was the press release dated?

The press release is dated November 6, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 08:00 AM Learn about SEC filing dates

false 0001668243 0001668243 2025-11-06 2025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

UROGEN PHARMA LTD.

(Exact name of registrant as specified in its charter)

Israel	001-38079	98-1460746
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

400 Alexander Park Drive, 4th Floor Princeton, New Jersey		08540
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +1 (646) 768-9780

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value NIS 0.01 per share		URGN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition

On November 6, 2025, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number		Description
99.1		Press Release dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2025	UROGEN PHARMA LTD.
	By:	/s/ Chris Degnan
		Chris Degnan
		Chief Financial Officer